A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn's Disease Improves Outcomes at 2 Years.

Giulia D'ArcangeloGiusy RussoMarina AloiCosimo RuggieroFrancesca MaccioniCesare HassanPaola PapoffStanley Allen CohenSalvatore Oliva

Published in: Inflammatory bowel diseases (2023)

When a PCE-based, treat-to-target strategy is employed, MH is sustainable (93%) over a 1-year period and is correlated with improved patient outcomes, including reduced need for steroids, treatment escalation, hospitalization, and clinical relapses at 104 weeks.ClinicalTrials.gov number: NCT03161886.

Keyphrases

young adults
open label
type diabetes
metabolic syndrome
study protocol